SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day’s highlights from X/Twitter.
”SABCS23 Day 1 Highlights Community Oncology:
2. EMERALD
3. TDxD
4. Tumor Agnostic landscape
5. Post CDK4/6i HR+
– Pending OS,
– 400mg BID, 4days on/3days off.
most Benefit CDK4/6i >12mos,
– AE: musculoskeletal pain, nausea,
increased cholesterol.
– mFU 32mos, OS 23.9mos vs 17.6 mos (in Hr+, HR: 0.69),
– OS 22.9mos vs 16.8mos (in All Pts, HR: 0.69).
For the more information click here.
4. Tumor Agnostic landscape: 2017-22
– Pembro + Dostar in MSI-H. Pembro in High TMB,
– Larotrectinib + Entrectinib in NTRK,
– Dabrafenib/Trametinib in BRAF V600E,
– Selpercatinib in RET fusion.
For the more information click here.
5. What to do post CDK4/6i: phenomenal session!
– PARPi, AKT pathway, ESR1 or ADCs, everolimus and chemo are potential options. Switch CDK4/6i Rx might be an option,
– Abigail Johnston, one of the most moving talks I have EVER heard!”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023